News Articles
Latest articles, insights, and updates from the blog.
Have a question about this topic?
Use the contact page when you need to send feedback, request a correction, or ask about the resource.
Esketamine's Role in Treatment-Resistant Depression Care
Comparing ketamine-based options for treatment-resistant depression in 2026: how esketamine differs from generic ketamine and what to ask before choosing.
New PTSD Prevention Drug Trial: What It Means for Patients
A new DoD-backed Phase 2a trial tests BXCL501 for acute stress reactions. Here's what it means for ketamine patients seeking PTSD treatment in 2026.
Why 'Good Enough' Depression Care Is No Longer Enough
New clinical guidance pushes for true remission in treatment-resistant depression. Here's what that means for patients exploring ketamine therapy.
BPL-003 Trial Results: What They Mean for TRD Patients
New phase 2a data on BPL-003 shows lasting depression symptom reduction. Here's what it means for patients exploring ketamine and emerging TRD therapies.
New PTSD Prevention Drug Trial: What Patients Should Know
A new DoD-backed trial is testing BXCL501 for acute stress reactions. Here's what it means for ketamine patients pursuing PTSD treatment today.
Beyond 'Less Bad': New Push for True TRD Remission
Psychiatrists are shifting TRD goals from symptom reduction to full remission. Here's what that means for patients and ketamine therapy in 2026.